The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial

Conclusions. This is the first prospective trial testing the safety and efficacy of FMT in AML patients receiving intensive induction chemotherapy. The trial achieved its primary endpoint and established the capacity of FMT to restore a diverse microbiome with high levels of similarity to baseline, as well as reducing ARGC and intestinal inflammation. A controlled randomized trial with repeated FMT administrations is currently planned to further evaluate the impact of FMT on clinical outcomes and long-term survival. (This trial was funded by MaaT Pharma whose product was tested in this protocol).DisclosuresMohty: MaaT Pharma: Consultancy, Honoraria. Doré: MaaT Pharma: Consultancy, Honoraria.

Source: Blood - November 21, 2018 Category: Hematology Authors: Mohty, M., Malard, F., Vekhoff, A., Lapusan, S., Isnard, F., D'Incan, E., Rey, J., Saillard, C., Thomas, X., Ducastelle-Lepretre, S., Paubelle, E., Larcher, M. V., Rocher, C., Recher, C., Tavitian, S., Huguet, F., Michallet, A.-S., Gilis, L., Peterlin, P. Tags: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I Source Type: research